[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"1st-line-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:1st-line-nsclc":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100446799",false,"NCT05098132","Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","A Phase 1\u002F2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications","SYNERGY-101","Selected Inclusion Criteria:\n\n1. Phase 1: Selected advanced solid tumors\n2. Phase 2:\n\n   * Diagnosis of non-small cell lung cancer (NSCLC).\n   * Stage IV or Stage IIIB\u002FIIIC and not a candidate for definitive treatment.\n   * Non-squamous (NSQ) cell histology.\n   * No prior systemic therapy for advanced\u002Fmetastatic NSQ NSCLC.\n   * Must have a tumor that meets at least one of the following criteria on local testing:\n\n     * PD-L1 negative (TPS \\\u003C1%), OR;\n     * STK11 mutated on tumor tissue or ctDNA\n   * No known actionable EGFR, ALK, ROS1, or other actionable genomic aberrations for which there is a local standard of care available as front line therapy.\n\nSelected Exclusion Criteria:\n\n2\\. Phase 2:\n\n* Prior immune checkpoint inhibitor (anti-PD\\[L\\]1 and\u002For anti-CTLA-4) treatment\n* Rare tumor subtypes (mucinous histology or tumors with small cell, neuroendocrine, or sarcomatoid components).\n* Received radiotherapy ≤ 7 days of the first dose of study treatment.\n* Known active central nervous system metastases\n* Any history of carcinomatous meningitis","ALL","18 Years",{"count":19,"type":20},364,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a phase 1\u002F2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.",[27,28,29,30],"Advanced Solid Tumor","Non Small Cell Lung Cancer","Untreated Advanced NSCLC","1st Line NSCLC","RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2022-01-25",{"date":39,"type":20},"2029-01",{"name":41,"class":42},"Synthekine","INDUSTRY",47,""]